Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On February 27, 2025, Imunon, Inc. (IMNN) announced financial results for 2024 and provided a business update.</li><li>The company is currently finishing preparations to conduct a Phase 3 clinical trial of its lead development compound, IMNN-001, in the treatment of advanced ovarian cancer.</li><li>We anticipate the 500-patient trial will initiate before the end of the first quarter of 2025.</li></ul>

On February 27, 2025, Imunon, Inc. (IMNN) announced financial results for 2024 and provided a business update.The company is currently finishing preparations to conduct a Phase 3 clinical trial of its lead development compound, IMNN-001, in the treatment of advanced ovarian cancer.We anticipate the 500-patient trial will initiate before the end of the first quarter of 2025.

IMNN: Phase 3 Ovarian Cancer Trial to get Underway in Mar 2025 